Molecular Partners Yönetim

Yönetim kriter kontrolleri 2/4

Molecular Partners CEO'su Patrick Amstutz, Jan2004 tarihinde atandı, in görev süresi 20.83 yıldır. in toplam yıllık tazminatı CHF 1.05M olup, şirket hissesi ve opsiyonları dahil olmak üzere 36.8% maaş ve 63.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.99% ine doğrudan sahiptir ve bu hisseler € 3.82M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 4.6 yıldır.

Anahtar bilgiler

Patrick Amstutz

İcra Kurulu Başkanı

CHF 1.0m

Toplam tazminat

CEO maaş yüzdesi	36.8%
CEO görev süresi	20.8yrs
CEO sahipliği	2.0%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Patrick Amstutz'un ücretlendirmesi Molecular Partners'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-CHF 63m
Jun 30 2024	n/a	n/a	-CHF 58m
Mar 31 2024	n/a	n/a	-CHF 59m
Dec 31 2023	CHF 1m	CHF 385k	-CHF 62m
Sep 30 2023	n/a	n/a	-CHF 60m
Jun 30 2023	n/a	n/a	-CHF 62m
Mar 31 2023	n/a	n/a	-CHF 50m
Dec 31 2022	CHF 1m	CHF 383k	CHF 118m
Sep 30 2022	n/a	n/a	CHF 117m
Jun 30 2022	n/a	n/a	CHF 118m
Mar 31 2022	n/a	n/a	CHF 106m
Dec 31 2021	CHF 1m	CHF 380k	-CHF 64m
Sep 30 2021	n/a	n/a	-CHF 67m
Jun 30 2021	n/a	n/a	-CHF 72m
Mar 31 2021	n/a	n/a	-CHF 66m
Dec 31 2020	CHF 1m	CHF 380k	-CHF 63m
Sep 30 2020	n/a	n/a	-CHF 53m
Jun 30 2020	n/a	n/a	-CHF 48m
Mar 31 2020	n/a	n/a	-CHF 43m
Dec 31 2019	CHF 930k	CHF 363k	-CHF 36m
Sep 30 2019	n/a	n/a	-CHF 37m
Jun 30 2019	n/a	n/a	-CHF 38m
Mar 31 2019	n/a	n/a	-CHF 38m
Dec 31 2018	CHF 909k	CHF 346k	-CHF 37m
Sep 30 2018	n/a	n/a	-CHF 27m
Jun 30 2018	n/a	n/a	-CHF 18m
Mar 31 2018	n/a	n/a	-CHF 24m
Dec 31 2017	CHF 885k	CHF 344k	-CHF 25m

Tazminat ve Piyasa: Patrick 'nin toplam tazminatı ($USD 1.18M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 852.77K ).

Tazminat ve Kazançlar: Patrick şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Patrick Amstutz (49 yo)

20.8yrs

Görev süresi

CHF 1,047,000

Tazminat

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Patrick Amstutz	Co-Founder	20.8yrs	CHF 1.05m	1.99% € 3.8m
Michael Stumpp	Co-Founder	20.8yrs	Veri yok	2.08% € 4.0m
Robert Hendriks	Senior VP of Finance	5.3yrs	Veri yok	Veri yok
Alexander Zurcher	COO & Member of Management Board	2.3yrs	Veri yok	0.070% € 133.5k
Renate Gloggner	Executive VP of People & Community and Member of Management Board	2.9yrs	Veri yok	0.062% € 119.4k
Daniel Steiner	Senior Vice President of Research & Technology	3.7yrs	Veri yok	Veri yok
Seth Lewis	Senior Vice President of Investor Relations	no data	Veri yok	Veri yok
Michael Pitzner	General Counsel	2yrs	Veri yok	Veri yok
Pamela Trail	Strategic Consultant	5.3yrs	Veri yok	Veri yok
Anne Goubier	Senior Vice President of Research & Early Development	2.8yrs	Veri yok	Veri yok
Philippe Legenne	Chief Medical Officer	1.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 6ML0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Patrick Amstutz	Co-Founder	7.1yrs	CHF 1.05m	1.99% € 3.8m
Steven H. Holtzman	Independent Non Executive Director	10.5yrs	CHF 135.00k	0.040% € 76.4k
William A. Burns	Independent Chairman of the Board	7.1yrs	CHF 295.00k	0.073% € 139.9k
Vito Palombella	Independent Director	4.6yrs	CHF 125.00k	0.0095% € 18.2k
Agnete Fredriksen	Independent Director	3.6yrs	CHF 125.00k	Veri yok
Michael Vasconcelles	Independent Director	4.6yrs	CHF 135.00k	0.0095% € 18.2k
Sandip Kapadia	Independent Director	4.6yrs	CHF 130.00k	0.0095% € 18.2k
Dominik Hochli	Independent Director	3.6yrs	CHF 133.00k	Veri yok

4.6yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6ML0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).

Molecular Partners Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG Announces Executive Changes

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Molecular Partners AG Announces Executive Changes

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş